IGC Pharma, Inc. (IGC) stock
Close on Nov 11, 2026Market cap $20.56MP/E –Yield –
IGC Pharma, Inc. saw revenue fall 15.4% to $1.12M over the twelve months to Jun 30, 2026. At the latest close the market valued the company at $20.56M.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Sep 30, 2026
Valuation
- Market cap
- $20.56M
- P/E ratio
- –
- Price to sales
- 18.31
- Price to book
- 3.16
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Revenue
- $1.12M
- Net income
- -$7.89M
- EPS, diluted
- -$0.08
Trading
- Previous close
- $0.20
- Open
- $0.20
- Day's range
- $0.19 – $0.20
- Volume
- 193,411
- Average volume (20 days)
- 486,060
- Beta (5 years)
- 0.61
- 52-week range
- $0.08 – $0.40
- RSI (14 days)
- 36.0
- Volatility (1 year)
- 53.1%
- Relative volume
- 0.30×
- WACC
- 7.9%
Market cap history
Month-end market cap since 2012, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 11, 2026. The S&P 500 is measured by the SPY fund.
| Period | IGC | S&P 500 | Difference | IGC per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -28.9% | -2.4% | −26.5 pts | ||
| 3 months | -29.2% | -1.2% | −28.1 pts | ||
| Year to date | -29.3% | +12.3% | −41.6 pts | ||
| 1 year | -48.6% | +12.4% | −61.0 pts | ||
| 3 years | -32.6% | +78.8% | −111.4 pts | -12.3% | +21.4% |
| 5 years | -86.1% | +75.2% | −161.3 pts | -32.6% | +11.9% |
| 10 years | -45.5% | +311.1% | −356.6 pts | -5.9% | +15.2% |
Fifteen years at a glance
Fiscal years 2012 to 2026 and trailing twelve months, USD
Revenue
Gross profit
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases IGC Pharma filed with the SEC as exhibits to Form 8-K or 6-K
- Update
- News
- News
- News
- News
- Update
About IGC Pharma
Pharmaceutical Preparations
IGC Pharma, Inc. is a clinical-stage biotechnology company focused on developing therapies to treat and diagnose central nervous system disorders, primarily Alzheimer’s disease. The company operates in a single reportable segment, Life Sciences, having previously realigned away from its legacy Infrastructure activities. Its product pipeline centers on innovative drug candidates targeting neurodegenerative conditions, notably its lead candidate IGC-AD1, which is undergoing clinical evaluation for agitation associated with Alzheimer’s dementia. Additionally, the company advances preclinical therapeutic candidates targeting amyloid-beta plaque formation and metabolic disorders, while applying artificial intelligence and machine learning models to identify early diagnostic markers and optimize clinical trials.
Company profile, executives and historyIGC Pharma stock: common questions
What is IGC Pharma's stock price?
IGC closed at $0.20 on Nov 11, 2026, up 1.48% on the day. Over the past 52 weeks it traded between $0.08 and $0.40.
What is IGC Pharma's market cap?
IGC Pharma was worth $20.56M at the close on Nov 11, 2026: the share price times the diluted shares outstanding.
What is IGC's P/E ratio?
IGC Pharma lost money over the twelve months to Jun 30, 2026 (diluted EPS -$0.08), so it has no meaningful P/E ratio.
How much revenue does IGC Pharma make?
IGC Pharma reported revenue of $1.12M for the twelve months to Jun 30, 2026, down 15.4% from a year earlier.
Does IGC Pharma pay a dividend?
No. IGC Pharma has not paid a cash dividend over the last twelve months.
How has IGC stock performed over the past year?
Including dividends, IGC returned -48.6% over the past year, against +12.4% for the S&P 500.
How many IGC shares are sold short?
0M shares were sold short at the latest FINRA report, 0.44% of the float, or 1.0 days of average trading volume.
Who are IGC Pharma's competitors?
Companies most similar to IGC Pharma by business, industry and size include SPRB, BTAIQ, LGVN, OVID, MNOV.
See a number that looks wrong?